BOSTON, July 29, 2025 /PRNewswire/ -- Athena Diagnostics, the specialty neurology business of Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced a ...
Recent reports in Europe and the United States raise concern about the potential negative impact of gene patents on the freedom to operate of diagnosticians and on the access of patients to genetic ...
Most cases of FXTAS published thus far were ascertained through families with a known fragile-X proband. Since cerebellar ataxia is one of the main cardinal features, we decided to perform fragile X ...
New test utilizes technology based on PacBio's PureTarget sequencing method to uncover genetic causes of disease BOSTON, July 29, 2025 /PRNewswire/ -- Athena Diagnostics, the specialty neurology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback